Our goal is to facilitate research that will bring new treatments to those suffering from neurodegenerative diseases. We fund researchers that have projects intended to bring new hope to ALS patients.
NDR, Inc. is a not-for-profit organization that was formed with a mission to provide funding to researchers with an emphasis to identify and validate biomarkers for determining drug effectiveness in neurodegenerative diseases and facilitate pathology-based treatments to the ALS patient. NDR supports open access to all findings via peer reviewed publications.
NDR funded projects include: identifying markers for stressed tissue from adipose derived stem cells, investigating immune checkpoint cell signaling, in vitro analysis of perivascular stem cell repair of cell damage, evaluating cytokine responses of treated peripheral blood mononuclear cells, studies using SOD1 mouse models of ALS, evaluating the components of conditioned media from various sources, development of secretome as an ALS treatment, and modification of therapeutic molecules to increase effectiveness and decrease toxicity in ALS patients. Using DNA and RNA analysis that define ALS phenotypes and metabolomic studies including metabolomics and miRNA studies are also funded avenues of research.